Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TSC-204-C0702 |
| Trade Name | |
| Synonyms | TSC204-C0702|TSC 204-C0702 |
| Drug Descriptions |
TSC-204-C0702 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-C*07:02, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing MAGE-A1 (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C201132 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TSC-200-A0201 + TSC-204-C0702 | TSC-200-A0201 TSC-204-C0702 | 0 | 1 |
| TSC-201-B0702 + TSC-204-C0702 | TSC-201-B0702 TSC-204-C0702 | 0 | 1 |
| TSC-203-A0201 + TSC-204-C0702 | TSC-203-A0201 TSC-204-C0702 | 0 | 1 |
| TSC-204-A0101 + TSC-204-C0702 | TSC-204-A0101 TSC-204-C0702 | 0 | 1 |
| TSC-204-A0201 + TSC-204-C0702 | TSC-204-A0201 TSC-204-C0702 | 0 | 1 |
| TSC-204-C0702 | TSC-204-C0702 | 0 | 1 |